全人源抗IL-7Rα抗体B12对T细胞急性淋巴细胞白血病具有抗肿瘤活性
研究通过噬菌体展示库与抗体改造获得全人源IgG1单克隆抗体B12,靶向野生型及突变型IL-7Rα。B12可削弱IL-7/IL-7R信号、使T-ALL细胞对地塞米松敏感并直接诱导细胞死亡,体外促进NK介导的抗体依赖细胞毒作用,体内延缓T细胞白血病发展、降低肿瘤负荷并延长小鼠生存。B12快速内化并转运至溶酶体,其MMAE偶联物较裸抗体增强杀伤白血病细胞的能力。
要点
- B12为全人源IgG1单抗,可结合野生型及突变型IL-7Rα,并削弱IL-7/IL-7R信号。
- B12使T-ALL细胞对地塞米松敏感,并可直接诱导细胞死亡。
- B12-MMAE偶联物较裸抗体增强杀伤白血病细胞的能力。
核心结论
- B12通过削弱IL-7/IL-7R信号、增敏地塞米松、诱导细胞死亡、促进NK介导的抗体依赖细胞毒作用及体内延缓T细胞白血病发展发挥抗肿瘤活性。
- B12快速内化并转运至溶酶体,其MMAE偶联物较裸抗体增强杀伤白血病细胞的能力,为T-ALL靶向治疗开发提供概念验证。
研究设计与样本
- 利用组合噬菌体展示库与抗体改造,生成全人源IgG1单克隆抗体B12。
- 体外评估B12对IL-7/IL-7R信号、地塞米松敏感性、细胞死亡及NK介导抗体依赖细胞毒作用的影响;体内评估对T细胞白血病发展、肿瘤负荷及小鼠生存的影响。
主要发现
- B12可结合野生型及突变型人IL-7Rα,预测在与IL-7不同位点形成稳定复合物。
- B12削弱IL-7/IL-7R介导的信号,使T-ALL细胞对地塞米松敏感,并可直接诱导细胞死亡。
- B12在体外促进NK介导的抗体依赖白血病细胞毒作用。
- B12在体内延缓T细胞白血病发展,降低肿瘤负荷并促进小鼠生存。
- B12快速内化并转运至溶酶体,B12-MMAE偶联物较裸抗体增强杀伤白血病细胞的能力。
关键数值与推荐
- B12为全人源IgG1单克隆抗体,靶向野生型及突变型人IL-7Rα。
- B12-MMAE偶联物较裸抗体具有增强的白血病细胞杀伤能力。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer for which treatment options often result in incomplete therapeutic efficacy and long-term side-effects. Interleukin 7 (IL-7) and its receptor IL-7Rα promote T-ALL development and mutational activation of IL-7Rα associates with very high risk in relapsed disease. Using combinatorial phage-display libraries and antibody reformatting, we generated a fully human IgG1 monoclonal antibody (named B12) against both wild-type and mutant human IL-7Rα, predicted to form a stable complex with IL-7Rα at a different site from IL-7. B12 impairs IL-7/IL-7R-mediated signaling, sensitizes T-ALL cells to treatment with dexamethasone and can induce cell death per se. The antibody also promotes antibody-dependent natural killer-mediated leukemia cytotoxicity in vitro and delays T-cell leukemia development in vivo, reducing tumor burden and promoting mouse survival. B12 is rapidly internalized and traffics to the lysosome, rendering it an attractive vehicle for targeted intracellular delivery of cytotoxic cargo. Consequently, we engineered a B12-MMAE antibody-drug conjugate and provide proof-of-concept evidence that it has increased leukemia cell killing abilities as compared with the naked antibody. Our studies serve as a stepping stone for the development of novel targeted therapies in T-ALL and other diseases where IL-7Rα has a pathological role.
引用
- Akkapeddi P, Fragoso R, Hixon JA, et al. A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia. Leukemia. 2019. PMID: 30850736. doi:10.1038/s41375-019-0434-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。